The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

InnoCare doses first subject in Phase 1 trial of ICP-B161

Oct 30, 2026 02:01 (13h ago)

Verifying

InnoCare Pharma dosed the first subject in ICP-B161’s Phase 1 autoimmune-disease trial.
ICP-B161 targets TL1A and IL-23p19 and is designed for subcutaneous administration.
InnoCare has three approved drugs and more than ten candidates in clinical development.